A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

References

• Burke PJ, Karp JE, Braine HG, Vaughan WP. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 1977; 37: 2138–2146.
   PubMed Web of Science ®Google Scholar
• Geller RB, Burke PJ, Karp JE et al. Two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989; 74: 1499–1506.
   PubMed Web of Science ®Google Scholar
• Martino R, Guardia R, Altes A, Sureda A, Brunet S, Sierra J. Timesequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the Phase II GEMIA protocol. Haematologica 1999; 84: 226–230.
   PubMed Web of Science ®Google Scholar
• Woods WG, Kobrinsky N, Buckley JD et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996; 87: 4979–4989.
   PubMed Web of Science ®Google Scholar
• Karp JE, Donehower RC, Dole GB, Burke PJ. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-beta-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. Blood 1987; 69: 1134–1140.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Thomas X, Leblond V et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of etoposide, mitoxantrone, and cytarabine - 86 trial. J Clin Oncol 1995; 13: 11–18.
   PubMed Web of Science ®Google Scholar
• Thomas X, Cambier N, Taksin AL et al. Dose-escalation study ofsingle dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leuk Res 2000; 24: 957–963.
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710–4718.
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky ICJ, Head DR et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998; 91: 3607–3615.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Witz F, Lioure B et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780–787.
   PubMed Web of Science ®Google Scholar
• Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235–1244.
   PubMed Web of Science ®Google Scholar
• Sierra J, Szer J, Kassis J et al. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008; 8: 195.
   PubMed Web of Science ®Google Scholar
• Braess J, Spiekermann K, Staib P et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantrone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009; 113: 3903–3910.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of the acute myeloid leukemia: a report of the French-American-British (FAB) Cooperative Group. Ann Intern Med 1985; 103: 620–625.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Smith TL, Kantarjian H et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403–412.
   PubMed Web of Science ®Google Scholar
• World Health Organization Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, 1979.
   Google Scholar
• Alexander J, Dainish N, Berger Hi et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angio-graphy. N Engl J Med 1981; 300: 278–283.
   Web of Science ®Google Scholar
• Cheson BD, Cassileth PA, Head DR et al. Report of the National Cancer Institute-sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Shenkenberg TD, von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105: 67–81.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Alberts DS, Arlin Z et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combi-nation with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002–2009.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewiecz MZ, Carroll RR et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178–1184.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelo-suppressive chemotherapy. Ann Oncol 2003; 14: 29–35.
   PubMed Web of Science ®Google Scholar
• Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731.
   PubMed Web of Science ®Google Scholar
• Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006; 42: 2976–2981.
   PubMed Web of Science ®Google Scholar
• Wolf M, Bentley M, Marlton P et al. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 2344–2350.
   PubMed Web of Science ®Google Scholar
• Lopez A, Fernandez de Sevilla A, Castaigne S et al. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomized phase II study. Blood 2004; 104: 3311.
   Web of Science ®Google Scholar
• Kern W, Aul C, Maschmeyer G et al. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia: German AML Cooperative Group. Ann Hematol 1998; 77: 115–122.
   PubMed Web of Science ®Google Scholar
• Fiegl M, Hiddemann W, Braess J. Use of pegylated recombinant filgrastim (Pegfilgrastim) in patients with acute myeloid leukemia: pharmacokinetics and impact on leukocyte recovery. Leukemia 2008; 22: 1284–1285.
   PubMed Web of Science ®Google Scholar